It doesn't take long at all to compile and analyze mortality data. Alive or dead at 14 and 28 days.
No ambiguity.

The other 50 plus outcomes OK.

But if mortality differences were overwhelmingly positive for leronlimab" one would think that would be the first thing looked at and would come out quickly. The rest wouldn't matter as much.

Speaking of all outcomes, when do we expect to see everything from CD10? Is a publication preprint coming soon?